Financial Performance - The company's operating revenue for 2020 was CNY 175,564,990.41, representing a 30.86% increase compared to CNY 134,160,531.96 in 2019[18]. - The net profit attributable to shareholders of the listed company for 2020 was CNY 8,154,550.92, a decrease of 56.64% from CNY 18,806,368.87 in 2019[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 5,654,615.66, an increase of 120.01% compared to the previous year[19]. - The net cash flow from operating activities was -CNY 207,220,871.68, a decrease of 1,526.91% year-on-year[19]. - The total assets at the end of 2020 were CNY 556,140,141.52, representing a 107.26% increase from the end of 2019[19]. - The company reported a total revenue of CNY 175.56 million for 2020, representing a year-on-year increase of 30.86%[44]. - The net profit attributable to shareholders was CNY 8.15 million, a decrease of 56.64% compared to the previous year[44]. - The energy-saving technology service sector generated CNY 77.76 million, accounting for 44.29% of total revenue, with a year-on-year growth of 120.55%[47]. - Revenue from energy-saving product sales reached CNY 47.51 million, showing a significant increase of 288.32% compared to the previous year[47]. - The cell storage and testing services revenue grew by over 49% year-on-year, amounting to CNY 76.93 million[47]. Business Strategy and Focus - The company has shifted its main business focus to biomedicine and cell technology services since 2014, with an additional emphasis on environmental protection and energy-saving since 2016[16]. - The company is expanding its business into "smart parks," "smart scenic areas," and "smart municipal" projects, supported by new product developments like the lamp post base locator and multifunctional pole signage installation methods[63]. - The company is focusing on expanding its market presence in the stem cell storage and application sectors, which are crucial for treating various diseases[91]. - The company has established a solid foundation for sustainable operations through strategic partnerships and resource accumulation in the medical device and consumables sector[37]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has undergone a strategic adjustment in its major shareholder structure, with the largest shareholder holding 25.58% of the total shares[16]. - The company confirmed that all commitments made to minority shareholders were fulfilled on time[111]. - The company is currently fulfilling commitments related to maintaining its independence and ensuring no conflicts of interest with controlling shareholders[102]. - The company has maintained a good integrity status with no significant debts overdue during the reporting period[122]. Research and Development - The company initiated six independent R&D projects in 2020, including studies on umbilical cord mesenchymal stem cells and their applications[60]. - The company is actively involved in six R&D projects related to energy-saving and environmental protection, focusing on smart pole equipment and lighting solutions[61]. - The number of R&D personnel increased by 50.00% from 92 in 2019 to 138 in 2020, with the proportion of R&D personnel rising from 26.21% to 34.94%[64]. - The company has obtained several patents, including methods for isolating and culturing human adipose-derived stem cells and umbilical cord mesenchymal stem cells[34]. Market and Industry Context - The global stem cell market size is projected to reach USD 160 billion by 2021, with a compound annual growth rate of 24.2% from 2015[89]. - In Hunan province, the stem cell storage rate is less than 1%, indicating significant growth potential in the local market[89]. - The company is positioned in a rapidly growing sector, with the domestic stem cell industry experiencing a surge in development due to supportive government policies[87]. - The industry is facing challenges from global economic uncertainties, including the impact of the COVID-19 pandemic and trade tensions[92]. Financial Management and Expenses - Sales expenses increased by 8.30% to ¥37,615,545.51 compared to the previous year[58]. - Management expenses decreased by 23.25% to ¥30,536,753.48 due to the disposal of a subsidiary in the previous year[58]. - Financial expenses dropped significantly by 68.52% to ¥3,292,932.63, attributed to a substantial reduction in average financing scale[59]. - R&D investment decreased significantly by 67.93% from ¥15,515,677.43 in 2019 to ¥4,976,335.90 in 2020, with the proportion of R&D investment to operating revenue dropping from 11.57% to 2.83%[64]. Corporate Governance and Compliance - The company has established a robust corporate governance structure, complying with laws and regulations to protect shareholder rights[184]. - The company has not encountered any significant discrepancies between its governance practices and regulatory requirements set by the China Securities Regulatory Commission[187]. - Independent directors attended all 9 board meetings and 1 shareholder meeting, with no absences reported[192]. - The audit committee reviewed the annual audit plan and financial statements, ensuring effective communication with the auditing firm[196]. Employee and Management Structure - The company employed a total of 395 staff members, including 248 sales personnel and 21 production personnel[179]. - The total remuneration for directors, supervisors, and senior management in the reporting period amounted to 2.8635 million yuan[176]. - The company has no stock incentive plans for directors and senior management during the reporting period[178]. - The management team is composed of individuals with extensive experience in the pharmaceutical and financial sectors, contributing to informed decision-making[168].

Financial Performance - Operating revenue reached ¥62,619,419.35, marking a 108.24% increase year-on-year[7] - Net profit attributable to shareholders was -¥1,405,720.31, a decrease of 75.61% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥1,737,997.01, a decrease of 69.14% year-on-year[7] - The weighted average return on equity was -9.00%, down 143.31% from the previous year[7] - The basic earnings per share were -¥0.0045, a decrease of 75.61% compared to the same period last year[7] - The company reported a net loss for the third quarter of 2020, with specific figures not disclosed in the provided content[47] - The company reported a net loss of CNY 482.99 million as of September 30, 2020, compared to a loss of CNY 479.50 million at the end of 2019[66] - The net profit for the third quarter was 1,001,219.24 yuan, compared to a net loss of 6,260,340.40 yuan in the same period last year, marking a significant turnaround[73] - The company reported a comprehensive income total of 1,001,219.24 yuan for the third quarter, contrasting with a comprehensive loss of 5,943,521.11 yuan in the previous year[74] - The total profit for Q3 2020 was CNY 1,790,323.98, recovering from a total loss of CNY -19,587,959.03 in the same quarter last year[81] Assets and Liabilities - Total assets increased to ¥386,581,186.94, representing a 44.07% increase compared to the previous year[7] - Cash and cash equivalents increased by 114.26% to ¥148,679,469.36 due to shareholder loans received during the period[15] - Accounts receivable rose by 161.43% to ¥97,859,036.05, reflecting increased business activity[15] - Total liabilities increased to CNY 266.01 million from CNY 153.87 million, reflecting a rise of 72.5%[65] - Current liabilities rose to CNY 262.40 million from CNY 149.60 million, an increase of 75.5%[65] - Total assets amounted to CNY 268,330,903.67, with current assets at CNY 143,586,227.13 and non-current assets at CNY 124,744,676.54[96] - Total liabilities reached CNY 153,874,879.03, with current liabilities at CNY 149,604,859.10 and non-current liabilities at CNY 4,270,019.93[98] Cash Flow - The company reported a net cash flow from operating activities of -¥6,853,622.38, a decrease of 44.54%[7] - The net cash flow from operating activities was -6,853,622.38 CNY, compared to -4,741,667.99 CNY in the previous period, indicating a decline in operational cash flow[89] - Total cash inflow from investment activities was 109,252,054.32 CNY, significantly higher than 33,058,836.54 CNY in the previous period, reflecting improved investment recovery[90] - The net cash flow from financing activities increased to 84,028,734.71 CNY from 9,396,046.35 CNY, showing a strong financing position[90] - The total cash and cash equivalents at the end of the period reached 148,679,469.36 CNY, up from 57,371,061.22 CNY in the previous period, indicating a substantial increase in liquidity[90] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,676[11] - The largest shareholder, Hunan Caixin Industrial Fund Management Co., Ltd., holds 25.58% of the shares[11] - Total equity attributable to shareholders decreased to CNY 14.92 million from CNY 18.41 million, a decline of 19.8%[66] - Total equity amounted to ¥22,826,172.59, with a significant negative retained earnings of ¥-380,060,325.40[103] Government Support and Investments - The company received government subsidies amounting to ¥1,134,622.47 during the reporting period[8] - Other income increased by 678.94% to ¥654,622.47, attributed to new government subsidies for energy-saving renovations[15] - The company has approved a proposal to invest 100 million RMB in a health industry investment fund, which has a total scale of 500 million RMB, focusing on stem cell and immune cell storage and treatment[25] Corporate Governance and Compliance - The company has not faced any significant administrative penalties or criminal responsibilities in the last three years[37] - The company has committed to comply with national laws and regulations since January 1, 2017, and has not been under investigation by judicial authorities[37] - The company assures that all information provided during the asset restructuring process is true, accurate, and complete, with no misleading statements or omissions[36] - The company guarantees that any related transactions with Nanhua Biological will be conducted at fair market prices and in compliance with relevant laws and regulations[31] - The company has pledged to not utilize its controlling shareholder status to harm the legal rights of Nanhua Biological and its other shareholders[32] Research and Development - Research and development expenses decreased by 47.60% to ¥3,920,467.46, due to the disposal of a subsidiary[15] - Research and development expenses for the third quarter were 1,265,526.81 yuan, down from 1,798,338.07 yuan year-on-year, reflecting a decrease of approximately 29.4%[72] Future Plans - The company plans to relocate its headquarters and related subsidiaries to Changsha National High-tech Industrial Development Zone, establishing a research and production base for stem cell and immune cell technology[21] - The company plans to focus on expanding its market presence and investing in new product development to drive future growth[66]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥42,037,618.31, a decrease of 30.13% compared to ¥60,164,210.91 in the same period last year[17]. - The net profit attributable to shareholders was a loss of ¥2,090,149.71, an improvement of 85.41% from a loss of ¥14,324,100.57 in the previous year[17]. - The net cash flow from operating activities was negative at ¥1,153,404.04, a decline of 253.62% compared to a positive cash flow of ¥750,826.57 in the same period last year[17]. - The basic earnings per share were -¥0.007, showing an improvement of 84.78% from -¥0.0460 in the previous year[17]. - The total operating revenue for the reporting period was CNY 42.04 million, representing a decline of 30.13% compared to the previous year[32]. - The company reported a net profit attributable to the parent company of CNY -2.09 million, a year-on-year improvement of 85.41% in loss reduction[32]. - The company reported a significant drop in operating income due to the impact of COVID-19, with many markets unable to operate for nearly three months[52]. - The total operating costs for the first half of 2020 were CNY 41,971,565.17, down 41.7% from CNY 71,928,244.53 in the same period last year[144]. - The company reported a comprehensive income loss of 12.44 million yuan for the current period, indicating a significant decline in profitability[171]. Assets and Liabilities - Total assets at the end of the reporting period were ¥236,257,904.87, down 11.95% from ¥268,330,903.67 at the end of the previous year[17]. - The net assets attributable to shareholders decreased by 11.35% to ¥16,323,829.76 from ¥18,413,979.47 at the end of the previous year[17]. - The company's cash and cash equivalents decreased to CNY 44,858,962.65, down 4.34% from CNY 82,803,389.76 in the previous year[41]. - The total liabilities decreased to CNY 116,684,514.17 from CNY 153,874,879.03, reflecting a reduction of 24.2%[139]. - The total current liabilities decreased to CNY 112,857,700.29 from CNY 149,604,859.10, indicating a decline of 24.6%[139]. - The company reported a decrease in long-term equity investments from CNY 17,198,407.77 to CNY 6,615,997.85, a decline of approximately 61.54%[137]. Revenue Segments - The company's revenue for the biopharmaceutical segment was CNY 34.84 million, a decrease of 27.32% year-on-year, while the energy-saving and environmental protection segment generated CNY 7.20 million, down 41.14% year-on-year[25]. - Stem cell storage and testing revenue reached CNY 34,741,095.23, a significant increase of 63.51% year-on-year, accounting for 82.64% of the total revenue[38]. - The antibody product sales and technical service revenues both experienced a 100% decline due to the disposal of the subsidiary Yuan Tai Bio[39]. Strategic Initiatives - The company aims to expand its business scale and enhance revenue sources to improve profitability, as current income levels are insufficient to cover overall costs[32]. - The company has established strategic partnerships with 228 hospitals and signed contracts with 120 hospitals for stem cell storage services[28]. - The company plans to enhance brand awareness and improve employee training to increase the conversion rate of newborn stem cell storage[53]. - The company aims to diversify its product line by expanding into adult immune cell and adipose-derived stem cell storage projects to mitigate the impact of declining birth rates[53]. - The company intends to increase investment in technology and hardware to develop new downstream products and clinical applications, creating new growth points[53]. Governance and Compliance - The company has not faced any significant administrative penalties or criminal liabilities in the last three years[71]. - The company has complied with national laws and regulations since January 1, 2017, and has not been subject to any criminal investigations[74]. - The company guarantees the authenticity, accuracy, and completeness of the information provided, ensuring no misleading statements or omissions exist[70]. - The company has committed to transparency and compliance with disclosure obligations, with no undisclosed contracts or agreements[70]. - The company has not engaged in any significant asset or equity sales during the reporting period[47]. Financial Management - The company has a total of 1,650 million yuan in entrusted financial management, with no overdue amounts[106]. - The company incurred a credit impairment loss of CNY -1,314,455.88, compared to CNY -824,933.80 in the previous year[146]. - The company reported a significant increase in cash received from investment recoveries, totaling 61,005,745.00 yuan, compared to 31,800,000.00 yuan previously[155]. - The company has not announced any shareholding reduction plans[78]. - The company has not experienced any bankruptcy restructuring during the reporting period[86]. Research and Development - The company’s R&D investment decreased by 53.29% year-on-year to CNY 2.65 million, reflecting a reduction in operational scale following the disposal of a subsidiary[34]. - The company plans to continue its investment in research and development for new products and technologies[161]. Market Conditions - The biopharmaceutical segment faces risks due to a declining birth rate in Hunan, with newborn numbers dropping from 908,000 in 2017 to 718,000 in 2019, which may reduce the potential customer base[51]. - The company is focusing on internal cost reduction and efficiency improvements to stabilize performance and expand market coverage[53].

Financial Performance - The company reported a positive net profit for 2019, reversing the negative net profits of the previous two years[4]. - The end-of-year net assets for 2019 were also positive, allowing the company to apply for the removal of the delisting risk warning[4]. - The company's operating revenue for 2019 was CNY 134.16 million, an increase of 40.66% compared to CNY 95.38 million in 2018[19]. - The net profit attributable to shareholders was CNY 18.81 million, a significant turnaround from a loss of CNY 35.19 million in 2018, representing a 153.44% increase[19]. - The net cash flow from operating activities improved to CNY 14.52 million, compared to a negative cash flow of CNY 15.19 million in the previous year, marking a 195.62% increase[20]. - The company reported a basic earnings per share of CNY 0.06, compared to a loss of CNY 0.11 per share in 2018, reflecting a 153.44% improvement[20]. - In 2019, the company's total revenue reached CNY 134.16 million, representing a year-on-year growth of 40.66%[37]. - The net profit attributable to the parent company was CNY 18.81 million, marking a turnaround from losses[37]. Business Segments - The revenue from the biopharmaceutical segment reached CNY 98.90 million, up 42.74% year-on-year, while the energy-saving and environmental protection segment generated CNY 35.26 million, a 35.13% increase[29]. - The biopharmaceutical sector accounted for 73.72% of total revenue, with a year-on-year growth of 42.74%[40]. - The energy-saving technology service sector generated CNY 35.26 million, accounting for 26.28% of total revenue, with a growth of 35.13%[40]. - The revenue from stem cell storage and testing services increased by over 170% compared to 2018[33]. Shareholder Information - The largest shareholder, Caixin Fund, holds 25.58% of the total shares after a strategic transfer of shares from Caixin Financial Holdings[17]. - The company’s stock is listed on the Shenzhen Stock Exchange under the ticker *ST Bio[14]. - The company has no major changes in asset measurement attributes as of the end of the reporting period[66]. - The total number of shares is 311,573,901, with 99.71% being unrestricted shares[140]. - Hunan Caixin Industrial Fund Management Co., Ltd. holds 25.58% of the shares, totaling 79,701,655 shares, with no changes during the reporting period[143]. Cash Flow and Investments - The company achieved a net increase in cash and cash equivalents of ¥10,378,519.59, a turnaround from a net decrease of ¥107,563,301.50 in the previous year, marking a 109.65% improvement[59]. - Investment activities generated a net cash inflow of ¥81,252,196.03, a substantial increase of 442.18% compared to the previous year[59]. - The company reported a total investment in securities amounting to 1,766,800,000 CNY with a fair value of 782,649,000 CNY at the beginning of the period[68]. - The total investment in securities at the end of the reporting period was 2,197,400,000 CNY, with a fair value of 1,085,500,000 CNY[69]. Research and Development - Research and development expenses decreased by 3.45% to ¥15,515,677.43, indicating a focus on optimizing key technologies and improving product quality[50]. - The company is advancing the development of mouse-derived monoclonal antibodies and rabbit-derived monoclonal antibody projects, alongside exploratory clinical projects in CAR-T cell therapy[51]. - Six R&D projects were initiated in 2019 to enhance product quality and service, including studies on umbilical cord mesenchymal stem cell cryopreservation solutions[52]. - The number of R&D personnel increased by 43.75% to 92, accounting for 26.21% of the total workforce[57]. Corporate Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring transparency and protection of shareholder rights[172]. - The company maintains an independent operational structure, with no interference from the controlling shareholder in decision-making or operational activities[176]. - The audit committee actively reviewed the company's audit plans and financial statements, ensuring effective communication with the external auditor[183]. - The company has no penalties from securities regulatory agencies for directors and supervisors in the past three years[164]. Strategic Initiatives - The company is focused on business expansion and supplementing its operations to strengthen its market position[74]. - The company is committed to reducing production costs and increasing the supply of green products as part of its strategic initiatives[84]. - The company aims to improve its financial situation by reducing financial costs and enhancing asset quality through strategic investments[74]. - The company is actively involved in the development of new biomedical technologies, aligning with national policies that encourage innovation in this sector[80]. Legal and Compliance - The company has not faced any significant administrative penalties or criminal liabilities in the last three years[95]. - The company has committed to comply with national laws and regulations since January 1, 2017, without any significant violations[95]. - The company has provided assurances regarding the authenticity and completeness of information related to major asset sales[95]. - The company is involved in a legal dispute regarding a technology licensing agreement, with a claim for remaining licensing fees of CNY 5 million, overdue payment penalties of CNY 2.005 million, and sales commission fees of CNY 374,900[109]. Employee and Management - The total number of employees in the company is 351, with 230 in sales, 25 in production, 17 in technical roles, 15 in finance, and 64 in administration[166]. - The company emphasizes a performance-based compensation policy, linking income levels to company performance and long-term interests[167]. - The company conducts various training programs, including internal, external, and online training, to enhance employee skills and knowledge[169]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 3.861 million yuan[165].

Financial Performance - The company's operating revenue for Q1 2020 was ¥18,507,279.73, a decrease of 37.84% compared to ¥29,775,813.30 in the same period last year[7] - The net profit attributable to shareholders was -¥1,600,061.19, an improvement of 75.56% from -¥6,546,948.14 year-on-year[7] - The net cash flow from operating activities was -¥1,732,165.50, showing a significant improvement of 79.93% compared to -¥8,628,981.65 in the previous year[7] - The basic earnings per share were -¥0.005, a 74.32% improvement from -¥0.02 in the same period last year[7] - The weighted average return on net assets was -9.18%, a decrease of 57.59% from 48.41% in the previous year[7] - The net loss for the period was CNY 1,812,286.66, compared to a net loss of CNY 6,706,477.49 in the previous period[42] - The comprehensive income totalled a loss of CNY 562,222.11, compared to a loss of CNY 6,777,772.19 in the previous year[44] - The total profit for the first quarter was a loss of CNY 744,209.24, compared to a loss of CNY 6,675,271.43 in the previous year[43] Assets and Liabilities - The total assets at the end of the reporting period were ¥237,530,539.91, down 11.48% from ¥268,330,903.67 at the end of the previous year[7] - The total current assets decreased to CNY 114,393,906.22 from CNY 143,586,227.13, indicating a decline of approximately 20.3%[33] - The company's total liabilities decreased from CNY 153,874,879.03 to CNY 123,636,737.38, reflecting a reduction of about 19.6%[36] - The total liabilities decreased to CNY 114,393,906.22 from CNY 143,586,227.13, indicating a reduction in financial obligations[34] - The total equity attributable to shareholders decreased from CNY 18,413,979.47 to CNY 16,813,918.28, a decline of about 8.7%[36] Cash Flow - Cash and cash equivalents decreased by 76.17% to ¥16,532,938.25 due to repayment of bank loans[15] - The company's cash and cash equivalents decreased significantly from CNY 30,239,191.44 to CNY 1,731,045.81, a decline of approximately 94.2%[36] - The cash inflow from operating activities was 5,155,296.01 CNY, compared to 1,023,922.69 CNY in the previous period, showing a significant increase[54] - The total cash outflow from operating activities was 23,017,021.48 CNY, compared to 40,340,294.31 CNY in the previous period[51] - The cash inflow from financing activities amounted to 120,000,000.00 CNY, while cash outflow was 30,272,358.34 CNY, leading to a net cash flow from financing activities of -30,272,358.34 CNY[52] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,764[11] - The largest shareholder, Hunan Caixin Industrial Fund Management Co., Ltd., held 25.58% of the shares, totaling 79,701,655 shares[11] Government Subsidies and Income - The company received government subsidies amounting to ¥54,068.02 during the reporting period[8] - Other income increased by 112.34% to ¥54,068.02, attributed to new government subsidies for energy-saving renovations[15] - Non-operating income surged by 2516.80% to ¥200,000.10, due to government rewards received[15] Operational Changes and Commitments - The company committed to maintaining its independence post-transaction, ensuring personnel, assets, and operations remain independent from controlling parties[18] - The company guarantees that its financial department and accounting system operate independently, allowing for independent financial decision-making and tax compliance[18] - The company reported a commitment to avoid related party transactions and ensure fair operations at market prices[19] - The company has committed to compensating for any direct or indirect economic losses caused by violations of these commitments[18] Compliance and Legal Matters - The company has complied with national laws and regulations since January 1, 2017, and has not faced significant administrative penalties or criminal investigations in the last three years[19] - There are no insider trading investigations related to the major asset sale, and the company has not faced any administrative penalties from the China Securities Regulatory Commission in the last 36 months[20] - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[29] Investment and Expenses - Cash paid for investments rose by 226.92% to ¥25,500,000.00, indicating increased purchases of bank wealth management products[16] - Research and development expenses fell by 68.78% to ¥1,028,258.63, again influenced by the disposal of YuanTai Bio[15] - The company incurred financial expenses of CNY 618,902.33, a decrease from CNY 3,132,019.91 in the previous period[46] - The company reported a significant reduction in management expenses to CNY 2,918,092.26 from CNY 2,010,598.28 in the previous period[46]

Financial Performance - Operating revenue for the reporting period reached ¥30,071,514.65, reflecting a 52.01% increase year-on-year[7] - Net profit attributable to shareholders was -¥5,764,294.89, a 23.75% increase in losses compared to the same period last year[7] - Basic earnings per share were -¥0.0185, a 23.87% increase in losses compared to the same period last year[7] - The company reported a net profit attributable to shareholders of -¥20,088,395.46 for the year-to-date, a 12.70% increase in losses compared to the same period last year[7] - Total operating revenue for the third quarter was CNY 30,071,514.65, an increase from CNY 19,781,947.78 in the previous period, representing a growth of approximately 52.5%[48] - Net loss for the period was ¥20,455,055.40, compared to a net loss of ¥23,341,174.52 in the same period last year, indicating an improvement[56] - The company reported a total comprehensive loss of ¥20,104,863.43, compared to a loss of ¥23,099,352.00 in the previous year[57] - The net cash flow from operating activities was -4,741,667.99 CNY, an improvement from -18,597,774.58 CNY in the previous period[63] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥343,792,611.18, representing a 0.32% increase compared to the end of the previous year[7] - Total current assets increased to CNY 164,034,216.14 as of September 30, 2019, up from CNY 146,449,877.19 at the end of 2018, representing a growth of approximately 12.1%[38] - Total liabilities increased to CNY 258,007,551.62 from CNY 234,954,728.31, representing an increase of approximately 9.8%[40] - Total non-current assets decreased to CNY 179,758,395.04 from CNY 196,255,869.11, a decline of about 8.4%[39] - The equity attributable to shareholders decreased to CNY -30,449,741.00 from CNY -10,250,391.21, indicating a decline in shareholder equity[41] - Total liabilities reached CNY 188,415,041.45, including current liabilities of CNY 187,415,041.45[79] Shareholder Information - The total number of shareholders at the end of the reporting period was 12,573[12] - The largest shareholder, Hunan Trust Co., Ltd., held 25.58% of the shares, totaling 79,701,655 shares[13] - The second-largest shareholder is in the process of transferring shares, with a price of RMB 21.95 per share, which is significantly higher than the current market price, leading to delays in payment arrangements[21] - The company received approval for the transfer of 79,701,655 shares (25.58% of total shares) from Hunan Guotou to Hunan Caixin Industrial Fund, indicating a strategic adjustment in shareholding structure[22] Cash Flow - Cash inflow from operating activities totaled 112,293,531.02 CNY, an increase from 86,394,181.79 CNY in the previous period[63] - Cash outflow from operating activities was 117,035,199.01 CNY, compared to 104,991,956.37 CNY in the previous period[63] - Cash inflow from investment activities was 33,058,836.54 CNY, down from 77,856,402.14 CNY in the previous period[65] - Cash outflow from investment activities was 39,629,869.97 CNY, compared to 133,431,457.10 CNY in the previous period[65] Expenses - Sales expenses surged by 103.81% to RMB 24,808,754.16 from RMB 12,172,774.42, primarily due to increased sales costs in stem cell storage services[17] - The company reported a significant increase in income tax expenses, rising 292.15% to RMB 867,096.37 from a tax benefit of RMB 451,256.11 in the previous period[17] - Research and development expenses for the quarter were CNY 1,798,338.07, down from CNY 2,901,604.11, indicating a reduction of approximately 38.2%[48] - Research and development expenses increased to ¥7,482,183.25, up from ¥5,836,478.18, reflecting a focus on innovation[54] Legal and Regulatory Matters - The company is currently involved in a lawsuit regarding a technology licensing agreement, with a claim for RMB 5 million in remaining fees and penalties[20] - The company plans to implement new financial instrument standards starting January 1, 2019, affecting asset classification[74] - The third quarter report was not audited, indicating potential limitations in the reliability of the financial data presented[80] Future Outlook - Future outlook includes potential market expansion and new product development strategies, although specific figures were not disclosed in the report[49] - The company has not disclosed any new product developments or market expansion strategies in the current report[80]

Financial Performance - The company's operating revenue for the first half of 2019 was ¥60,164,210.91, representing a 67.11% increase compared to ¥36,003,051.65 in the same period last year[16]. - The net profit attributable to shareholders of the listed company was -¥14,324,100.57, showing a 7.29% improvement from -¥15,449,940.11 in the previous year[16]. - The net cash flow from operating activities was ¥750,826.57, a significant increase of 110.31% compared to -¥7,282,835.69 in the same period last year[16]. - The total assets at the end of the reporting period were ¥354,869,892.42, which is a 3.55% increase from ¥342,705,746.30 at the end of the previous year[16]. - The net assets attributable to shareholders of the listed company decreased to -¥24,856,528.52, a decline of 142.49% from -¥10,250,391.21 at the end of the previous year[16]. - The basic earnings per share for the reporting period was -¥0.0460, a 7.31% improvement from -¥0.0496 in the same period last year[16]. - The weighted average return on net assets was 82.26%, a significant increase of 190.08% from -91.32% in the previous year[16]. - The company reported a net profit of -14.32 million CNY for the reporting period, with a net cash flow from operating activities of 0.7508 million CNY[49]. - The total profit (loss) for the first half of 2019 was reported at ¥-14,005,014.13, compared to ¥-14,813,633.28 in the same period of 2018, showing a reduction in losses[117]. - The total comprehensive loss for the first half of 2019 was ¥-14,161,342.32, compared to ¥-14,530,771.62 in the first half of 2018, indicating a decrease in comprehensive losses[118]. Revenue Segmentation - The revenue from the biopharmaceutical segment reached RMB 47,928,900, marking a significant growth of 117.60% compared to the same period last year[24]. - Revenue from the energy-saving technology service industry was CNY 12,235,273.52, a decrease of 12.46% year-over-year, with a gross margin of 27.27%[36]. - The biopharmaceutical industry generated revenue of CNY 47,928,937.39, an increase of 117.60% year-over-year, with a gross margin of 80.38%[36]. - Sales of stem cell storage and testing products reached CNY 21,247,279.23, up 303.08% year-over-year, with a gross margin of 83.31%[36]. - Domestic revenue was CNY 39,800,292.31, an increase of 78.39% year-over-year, with a gross margin of 59.18%[36]. - International revenue was CNY 20,363,918.60, an increase of 48.72% year-over-year, with a gross margin of 89.92%[36]. Expenses and Costs - Total operating costs increased to ¥71,928,244.53 in the first half of 2019, compared to ¥48,935,573.92 in the first half of 2018, marking a rise of about 47%[116]. - Research and development expenses increased by 93.67% to RMB 5,683,845.18, driven by higher spending in antibody business development[34]. - The sales expenses surged by 127.36% to RMB 16,170,865.49, correlating with the increase in revenue from the stem cell storage business[34]. - The company reported a financial expense of ¥6,532,248.25 in the first half of 2019, an increase from ¥5,945,005.31 in the same period of 2018[117]. Cash Flow and Financing - The company raised ¥120,000,000.00 through borrowings in the first half of 2019, compared to ¥50,000,000.00 in the same period of 2018[126]. - The net cash flow from financing activities was ¥21,332,294.97, a recovery from a net outflow of ¥25,376,453.67 in the previous year[126]. - The company’s cash and cash equivalents increased by RMB 23,790,733.10, a 133.90% rise compared to the previous year, due to improved cash flow from investment and financing activities[34]. - The company reported a significant increase in cash received from other operating activities, totaling ¥1,554,142.65, compared to ¥2,568,271.70 in the previous year[125]. Strategic Initiatives - The company is expanding its stem cell and immune cell storage business in Hunan Province, supported by local government policies[26]. - The company is actively pursuing mergers and acquisitions to enhance its core technology capabilities in the biopharmaceutical sector[26]. - The company plans to optimize its financing structure and reduce financing costs with the support of its controlling shareholders[49]. - The company aims to enhance its revenue capacity in the stem cell business by improving personnel productivity and reducing operational costs[49]. - The company plans to expand its biopharmaceutical business in 2019 through team integration, channel collaboration, and product diversification[59]. Risks and Challenges - The company faced risks and has outlined measures to address them in the report[5]. - The company is facing risks related to market competition and technological updates, which could impact its operational goals[49]. - The company has taken measures to ensure normal operations amid uncertainties regarding its going concern status[150]. - The company is expected to continue facing challenges in profitability and equity recovery in the near future[144]. Shareholder Information - The total number of shares remains at 311,573,901, with 99.71% being unrestricted shares[88]. - Hunan Trust Co., Ltd. held 25.58% of shares, totaling 79,701,655 shares[90]. - Shanghai Peaceful Bulk Equity Investment Fund Management Co., Ltd. held 11.43% of shares, totaling 35,600,000 shares[90]. - Chongqing Xinsanwei Investment Consulting Center (Limited Partnership) held 9.64% of shares, totaling 30,022,162 shares[90]. Compliance and Governance - The company did not engage in any major asset or equity sales during the reporting period[46]. - There are no major litigation or arbitration matters reported during the period[61]. - The company has not experienced any penalties or rectification issues during the reporting period[62]. - The integrity status of the company and its controlling shareholders remains good, with no significant debts overdue[63]. - The company did not engage in any related party transactions during the reporting period[65]. Financial Reporting and Audit - The financial report for the first half of 2019 was not audited[104]. - The company did not issue any preferred shares during the reporting period[96]. - The company has included several subsidiaries in its consolidated financial statements, expanding its operational scope[148].

Financial Performance - The company's revenue for Q1 2019 was ¥29,775,813.30, representing a 74.16% increase compared to ¥17,096,871.95 in the same period last year[8]. - The net profit attributable to shareholders was a loss of ¥6,546,948.14, an improvement of 9.89% from a loss of ¥7,265,661.50 in the previous year[8]. - The company's operating revenue increased by 74.16% to CNY 29,775,813.30 compared to CNY 17,096,871.95 in the previous period, driven by growth in stem cell storage and antibody business[15]. - The company reported a net loss of CNY 13,976,676.64 for Q1 2019, compared to a net loss of CNY 8,657,009.42 in the previous year[39]. - The comprehensive income totalled a loss of CNY 6,777,772.19, compared to a loss of CNY 6,364,539.58 in the prior period[43]. Cash Flow - The net cash flow from operating activities improved by 38.07%, with a net outflow of ¥8,628,981.65 compared to ¥13,934,062.63 in the same period last year[8]. - The company's cash flow from operating activities showed a significant increase, with cash received from operating activities rising by 68.51% to CNY 12,298,192.94[15]. - The cash flow from operating activities was CNY 30,536,901.97, showing an increase from CNY 21,338,542.81 in the previous period[49]. - The net cash flow from investing activities was -676,078.44 yuan, compared to -32,519,156.54 yuan previously, showing a substantial decrease in cash outflow[51]. - The company reported a net increase in cash and cash equivalents of 14,383,184.16 yuan, contrasting with a decrease of 48,869,433.73 yuan in the last period[51]. Assets and Liabilities - The total assets at the end of the reporting period were ¥360,972,527.49, a 5.33% increase from ¥342,705,746.30 at the end of the previous year[8]. - The company's total liabilities rose to CNY 259,999,281.69 from CNY 234,954,728.31, an increase of approximately 10.7%[34]. - The company's short-term borrowings increased significantly to CNY 140,000,000.00 from CNY 70,000,000.00, marking a 100% increase[37]. - The total current assets were CNY 59,004,735.29, with cash and cash equivalents at CNY 32,789,220.92[60]. - The total owner's equity was CNY 107,751,017.99, with minority interests at CNY 118,001,409.20[59]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,139[11]. - The largest shareholder, Hunan Trust Co., Ltd., held 25.58% of the shares, amounting to 79,701,655 shares[11]. - The company did not engage in any repurchase transactions during the reporting period[12]. Expenses - Research and development expenses rose by 108.88% to CNY 3,294,099.47, reflecting increased investment in antibody business[15]. - Sales expenses surged by 132.03% to CNY 7,091,789.60, correlating with the increase in revenue from stem cell storage services[15]. - Total operating costs for Q1 2019 were CNY 36,482,290.79, up from CNY 22,596,686.86, indicating a rise of about 61.3%[40]. - The financial expenses for the quarter amounted to CNY 3,132,019.91, an increase from CNY 2,695,049.10 in the previous year[45]. Compliance and Governance - The company has committed to ensuring that related party transactions do not harm the interests of shareholders, maintaining compliance with legal procedures[21]. - There were no reported violations regarding external guarantees or non-operational fund occupation by controlling shareholders during the reporting period[26][27]. - The company has not engaged in derivative investments during the reporting period, indicating a conservative approach to financial risk management[24]. - The company has not undergone an audit for the first quarter report[62].

Financial Performance - The company's operating revenue for 2018 was ¥95,381,715.10, representing a 41.53% increase compared to ¥67,392,990.10 in 2017[17]. - The net profit attributable to shareholders for 2018 was -¥35,188,300.29, a 5.20% improvement from -¥37,119,370.19 in 2017[17]. - The net cash flow from operating activities improved by 67.96%, reaching -¥15,187,479.97 in 2018 compared to -¥47,403,365.00 in 2017[17]. - The total assets at the end of 2018 were ¥342,705,746.30, a decrease of 15.33% from ¥404,775,978.06 at the end of 2017[17]. - The net assets attributable to shareholders were -¥10,250,391.21 at the end of 2018, a decline of 141.60% from ¥24,642,811.28 at the end of 2017[17]. - The basic earnings per share for 2018 was -¥0.11, an improvement of 8.33% from -¥0.12 in 2017[17]. - The weighted average return on net assets was -489.82% in 2018, a significant decline from 277.38% in 2017[17]. - The company has faced a continuous net profit loss for two consecutive years, leading to a risk warning for delisting[4]. Revenue Breakdown - The company's total revenue for the reporting period was CNY 39,596,715.67, with a quarterly breakdown of CNY 17,096,871.95 in Q1, CNY 18,906,179.70 in Q2, CNY 19,781,947.78 in Q3, and CNY 39,596,715.67 in Q4[21]. - The net profit attributable to shareholders for the entire year was -CNY 12,178,181.80, with quarterly losses of -CNY 7,265,661.50 in Q1, -CNY 8,184,278.61 in Q2, -CNY 7,560,178.38 in Q3, and -CNY 12,178,181.80 in Q4[21]. - The revenue from the biopharmaceutical segment reached CNY 69,291,900, representing a significant increase of 1110.79% year-over-year[26]. - The environmental protection segment reported revenue of CNY 26,089,800, a decrease of 57.69% compared to the previous year[26]. Acquisitions and Investments - The company acquired 54% equity in Yuantai Biotechnology and 51% equity in Aishipulin, leading to an increase in goodwill by 121.08%[27]. - The company's fixed assets increased by 84.58% due to the addition of new subsidiaries Yuantai Biotechnology and Aishipulin[27]. - The company plans to transfer 40% equity of Hunan Yuantai Biotechnology Co., Ltd. to Nanhua Bio, with the equity ownership being clear and complete[92]. - The company completed the acquisition of a 51% stake in Aisiplin, making it a subsidiary, and established a new company for stem cell storage with a registered capital of 500 million[141]. - The company acquired a 54% stake in Yuantai Biological, which has since become a subsidiary, and is planning to introduce third-party strategic investors for further development[142]. Research and Development - The company has established strategic partnerships with hospitals and research institutions to enhance its research and development capabilities[30]. - The company plans to leverage its R&D strengths to drive profitability, particularly through the development of CAR-T cell immunotherapy technologies[31]. - The company plans to undertake six R&D projects in 2018, focusing on key technologies related to stem cell preparation and storage services[54]. - All six R&D projects were completed on schedule, achieving expected goals and enhancing product quality and reliability[55]. - R&D personnel increased to 64, a 255.56% rise from 18 in 2017, with R&D expenditure reaching ¥16,069,891.41, up 488.87% year-on-year[59]. - R&D investment as a percentage of operating revenue rose to 16.85%, an increase of 12.80% compared to 4.05% in 2017, primarily due to high R&D spending by the newly acquired subsidiary[59]. Operational Changes and Strategies - The company has not made any changes to its main business operations since its listing[16]. - The company is actively exploring new business areas such as wastewater treatment and sludge treatment to create new revenue streams due to a significant decline in its energy-saving and environmental protection business[101]. - The company is focusing on expanding its market presence and enhancing its product offerings through strategic appointments and leadership changes[167]. - The company is positioning itself for growth by aligning its management structure with its long-term strategic goals in the biopharmaceutical market[169]. Governance and Compliance - The company has ensured that no related party transactions will harm the interests of both the controlling party and the company, adhering to fair and transparent market principles[90]. - The company has committed to avoiding any business activities that may conflict with its main operations, ensuring no direct or indirect competition arises[91]. - The company has no administrative penalties or criminal charges in the last five years, ensuring compliance with legal standards[93]. - The company has provided all necessary factual materials for the major asset restructuring, ensuring their authenticity and completeness[94]. - The company has confirmed that there are no insider trading investigations or penalties related to the major asset restructuring in the last 36 months[93]. Employee and Management Structure - The total number of employees is 365, with 350 from major subsidiaries and 15 from the parent company[178]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 3.27 million yuan[176]. - The company has a diverse board with members having backgrounds in law, finance, and management[176]. - The company is actively engaging in talent acquisition to strengthen its management team and enhance its competitive edge in the industry[167]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion RMB[95]. - New product development includes the launch of a novel drug expected to enter the market in Q3 2019, which is anticipated to generate an additional 200 million RMB in revenue[96]. - The company plans to invest 100 million RMB in new technology to improve production efficiency over the next year[95]. - The company has set a target to reduce operational costs by 5% in the upcoming year through various efficiency initiatives[95].

Financial Performance - Operating revenue for the reporting period was ¥19,781,947.78, an increase of 480.01% year-on-year, while year-to-date revenue reached ¥55,784,999.43, up 216.87% compared to the same period last year[8] - Net profit attributable to shareholders of the listed company was -¥7,560,178.38, a decrease of 10.58% year-on-year, with year-to-date net profit at -¥23,010,118.49, down 12.29%[8] - Basic earnings per share for the reporting period were -¥0.0243, a decrease of 10.33% year-on-year, while diluted earnings per share were also -¥0.0243[8] - The weighted average return on equity was -139.71%, compared to -281.66% in the previous year[8] Assets and Liabilities - Total assets at the end of the reporting period were ¥385,907,384.51, a decrease of 4.66% compared to the end of the previous year[8] - Net assets attributable to shareholders of the listed company were ¥1,763,276.95, down 92.84% from the previous year-end[8] - Cash and cash equivalents decreased by 60.42% to ¥65,937,508.89 due to payments for subsidiary acquisitions and repayment of bank and shareholder loans[16] - Accounts receivable increased by 173.89% to ¥14,285,599.47, attributed to new accounts from subsidiaries Yuantai Bio and Aishipulin[16] - Inventory rose by 46.15% to ¥36,220,559.77, driven by increases from subsidiaries Yuantai Bio and Aishipulin[16] Operating Activities - The net cash flow from operating activities was -¥18,597,774.58, a decrease of 63.36% year-on-year[8] - Cash received from operating activities increased by 52.77% to ¥80,478,899.29, reflecting higher sales from the newly acquired subsidiary Yuantai Bio[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,311[12] - The largest shareholder, Hunan Trust Co., Ltd., held 25.58% of the shares, amounting to 79,701,655 shares[12] Expenses - Sales expenses increased by 389.90% to ¥12,172,774.42, reflecting higher costs from subsidiaries Yuantai Bio and Aishipulin[17] - R&D expenses grew by 207.04% to ¥5,836,478.18, mainly due to increased spending from subsidiary Yuantai Bio[17] - The company reported a 6044.35% increase in other operating expenses to ¥1,497,679.08, due to the establishment of a non-profit organization[17] Investments - The company reported a total investment in securities amounting to 2,190.44 million yuan, with a fair value change of -713,209.95 yuan[20] - The company has invested 6,110 million yuan in bank wealth management products, with an unexpired balance of 4,050 million yuan[23] Financial Management - There were no overdue amounts or expected losses on the principal for the entrusted financial management[23] - The company did not engage in any derivative investments during the reporting period[24] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[26]